- Home
- KYTX vs CLLS Comparison
KYTX vs CLLS Comparison
Compare KYTX & CLLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KYTX
- CLLS
- Stock Information
- Founded
- KYTX 2018
- CLLS 1999
- Country
- KYTX United States
- CLLS France
- Employees
- KYTX N/A
- CLLS N/A
- Industry
- KYTX
- CLLS Biotechnology: Pharmaceutical Preparations
- Sector
- KYTX
- CLLS Health Care
- Exchange
- KYTX NYSE
- CLLS Nasdaq
- Market Cap
- KYTX 166.4M
- CLLS 148.1M
- IPO Year
- KYTX 2024
- CLLS 2007
- Fundamental
- Price
- KYTX $3.41
- CLLS $1.52
- Analyst Decision
- KYTX Buy
- CLLS Buy
- Analyst Count
- KYTX 5
- CLLS 3
- Target Price
- KYTX $23.20
- CLLS $7.00
- AVG Volume (30 Days)
- KYTX 308.0K
- CLLS 234.9K
- Earning Date
- KYTX 02-12-2025
- CLLS 11-04-2024
- Dividend Yield
- KYTX N/A
- CLLS N/A
- EPS Growth
- KYTX N/A
- CLLS N/A
- EPS
- KYTX N/A
- CLLS N/A
- Revenue
- KYTX N/A
- CLLS $36,042,000.00
- Revenue This Year
- KYTX N/A
- CLLS $387.77
- Revenue Next Year
- KYTX N/A
- CLLS $11.14
- P/E Ratio
- KYTX N/A
- CLLS N/A
- Revenue Growth
- KYTX N/A
- CLLS 46.96
- 52 Week Low
- KYTX $3.22
- CLLS $1.41
- 52 Week High
- KYTX $30.60
- CLLS $3.38
- Technical
- Relative Strength Index (RSI)
- KYTX 37.34
- CLLS 40.43
- Support Level
- KYTX $3.22
- CLLS $1.65
- Resistance Level
- KYTX $3.53
- CLLS $1.59
- Average True Range (ATR)
- KYTX 0.25
- CLLS 0.15
- MACD
- KYTX 0.00
- CLLS -0.03
- Stochastic Oscillator
- KYTX 13.46
- CLLS 7.14
About KYTX KYVERNA THERAPEUTICS INC
Kyverna Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on developing cell therapies for patients suffering from autoimmune diseases. Its product KYV-101, is an autologous CD19 CAR T-cell product candidate made from an underlying chimeric antigen receptor, or CAR. It is also developing KYV-201, an allogeneic therapy containing the same CAR as KYV-101, to develop it in multiple autoimmune diseases.
About CLLS Cellectis S.A.
Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC, product candidates in other therapeutic indications.